GeneChem-backed Akebia Therapeutics files for IPO
Akebia Therapeutics Inc, a Cambridge, Mass.-based biopharmaceutical company, has filed with U.S. regulatory authorities for a proposed initial public offering (IPO) of its common stock. The company plans to list on NASDAQ under the symbol AKBA. While no additional IPO information was released, a report from advisory firm Renaissance Capital said the company was set to raise up to US$75 million. Akebia is a portfolio investment of Canadian venture capital firm GeneChem. In 2013, GeneChem fund AgeChem participated in a US$41 million Series C financing of the company co-led by Satter Investment Management and Novo A/S. Founded in 2007, Akebia develops treatments for anemia and cancer.
18 February 2014•2 mins read
